NCT05704985: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors |
|
|
| Recruiting | 1 | 60 | US | DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Pembrolizumab, Nivolumab, Chemotherapy, Paclitaxel, Carboplatin, Oxaliplatin, Fluorouracil, Capecitabine | DEKA Biosciences | Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer | 09/24 | 02/25 | | |
